This article is more than 5 years old. Information may no longer be current.
Diabetes therapy highlights in honor of World Diabetes Day
Click Here to Manage Email Alerts
Today marks World Diabetes Day, established in 1991 by the International Diabetes Federation and the World Health Organization to raise awareness of the growing number of people affected by the disease. The date November 14 is the birthday of insulin discoverer Sir Frederick Banting.
Below are recent news reports with expert perspective published in Endocrine Today about developments in diabetes therapies.
Insulin patch proves effective for adults with type 2 diabetes
An insulin patch can safely provide similarly effective glycemic management in adults with type 2 diabetes compared with a standard insulin pen.
Oral insulin demonstrates safety, efficacy in phase 2b trial
Adults with type 2 diabetes assigned an oral formulation of human insulin achieved a clinically meaningful reduction in HbA1c compared with those assigned placebo.
FDA advisory committee rejects recommending approval of lower-dose empagliflozin for type 1 diabetes
The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 14-2 against recommending approval of a supplemental new drug application for the SGLT2 inhibitor empagliflozin 2.5 mg as an oral medication adjunct to insulin therapy for adults with type 1 diabetes, with committee members citing uncertainty regarding the adjudication of diabetic ketoacidosis and a lack of adequate data to support evidence for safety and efficacy.
Simultaneous combination therapy shows major potential in type 2 diabetes
When treating patients with type 2 diabetes, physicians may have more success if they use simultaneous combination therapy immediately rather than following the traditional stepped-up method of waiting to intensify treatment.
FDA approves first oral GLP-1 receptor agonist for diabetes
The FDA in September approved oral semaglutide, the first noninjectable GLP-1 receptor agonist for the treatment of type 2 diabetes.
FDA declines to approve sotagliflozin for type 1 diabetes
The FDA in March issued a complete response letter regarding a new drug application for oral sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor for adult with type 1 diabetes.
FDA grants breakthrough device designation for personalized, closed-loop insulin pump
The FDA February granted breakthrough device designation for a personalized, closed-loop insulin pump system that is currently in development from Medtronic.
Four strategies to obtain affordable insulin
As the cost for insulin continues to rise, clinicians can take several proactive steps to help uninsured and underinsured patients afford their medications today.
FDA approves first nasal glucagon powder for severe hypoglycemia
The FDA in July approved the first nasal glucagon powder for the emergency treatment of severe hypoglycemia in children and adults with diabetes.
PIONEER 8: Oral semaglutide reduces HbA1c, body weight as addition to insulin in type 2 diabetes
Oral semaglutide was shown to be superior to placebo for lowering HbA1c and body weight among adults with type 2 diabetes already taking insulin with or without metformin.